JYNT vs. EDAP, DSGN, SMTI, CDXS, IMMP, AKBA, GLUE, AXGN, SENS, and VMD
Should you be buying Joint stock or one of its competitors? The main competitors of Joint include Edap Tms (EDAP), Design Therapeutics (DSGN), Sanara MedTech (SMTI), Codexis (CDXS), Immutep (IMMP), Akebia Therapeutics (AKBA), Monte Rosa Therapeutics (GLUE), AxoGen (AXGN), Senseonics (SENS), and Viemed Healthcare (VMD). These companies are all part of the "medical" sector.
Edap Tms (NASDAQ:EDAP) and Joint (NASDAQ:JYNT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.
62.7% of Edap Tms shares are owned by institutional investors. Comparatively, 76.9% of Joint shares are owned by institutional investors. 0.2% of Edap Tms shares are owned by insiders. Comparatively, 30.2% of Joint shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Edap Tms had 7 more articles in the media than Joint. MarketBeat recorded 8 mentions for Edap Tms and 1 mentions for Joint. Edap Tms' average media sentiment score of 0.00 beat Joint's score of -0.01 indicating that Joint is being referred to more favorably in the news media.
Joint has higher revenue and earnings than Edap Tms. Joint is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.
Edap Tms currently has a consensus price target of $14.00, suggesting a potential upside of 108.64%. Joint has a consensus price target of $22.00, suggesting a potential upside of 27.76%. Given Joint's stronger consensus rating and higher probable upside, equities analysts plainly believe Edap Tms is more favorable than Joint.
Edap Tms has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Joint has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
Edap Tms received 65 more outperform votes than Joint when rated by MarketBeat users. Likewise, 62.84% of users gave Edap Tms an outperform vote while only 62.50% of users gave Joint an outperform vote.
Joint has a net margin of -9.24% compared to Joint's net margin of -30.12%. Edap Tms' return on equity of 3.94% beat Joint's return on equity.
Summary
Joint beats Edap Tms on 9 of the 17 factors compared between the two stocks.
Get Joint News Delivered to You Automatically
Sign up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
